
Bestselling author Colleen Hoover is sharing a health update with her many readers and fans.
The "It Ends with Us" author revealed she was diagnosed with cancer and underwent treatment in an Instagram story photo post Monday, writing, "Second to last day of radiation! I wish I could blame my hair and facial expressions on @texas.oncology but they've been great. Hope you never need them, but highly recommend them."
In an earlier Facebook post on Friday, Hoover wrote that she had received test results back from a geneticist that explained her cancer did not stem from "family genes" and was not tied to HPV or hormonal factors.
More people are living 5 years after cancer diagnosis, new data shows
She added that she was "happy and grateful to be alive."
Hoover has not revealed the type of cancer with which she was diagnosed.
The author was noticeably absent from the October 2025 premiere for the movie "Regretting You," which was adapted from her 2019 book of the same name.
"I'm super bummed, but am having an unavoidable surgery and can't travel for a while," Hoover wrote in an Instagram post at the time.
Hoover's latest book, "Woman Down," is out Jan. 13.
LATEST POSTS
- 1
Instructions to Investigate Different Open Record Extra Offers Actually - 2
Which Carrier Do You Suggest? Vote - 3
New hybrid mpox strain discovered in UK after US reports local spread - 4
The beauty advent calendar boom is here. Sephora kids are all in. - 5
Support Your Investment funds with These Individual accounting Thoughts
Our favorite Space.com stories of 2025
5 Family SUVs for 2024: Which One Accommodates Your Family's Needs\uff1f
Several Israelis attempt to cross into Gaza, escorted back to Israel by IDF
NASA's Apollo 8 moonshot saved 1968. Could Artemis 2 do the same in 2026?
Best Disney Palace: Which One Catches Your Creative mind?
Somaliland denies trading recognition with Israel for accepting Gazans
Extraordinary Shows to Long distance race on a Plane
EU delays signing of Mercosur free trade deal
Flu is rising rapidly, driven by a new variant. Here's what to know













